HKHiroaki Kawasaki

Hiroaki Kawasaki

*This is an algorithmically generated author record based on publicly available information.

Hiroaki Kawasaki has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Emi Igawa

    The Life Science Institute Ltd., 1-10-9 Kudankita, Chiyoda-ku, Tokyo 102-0073, Japan

    1 shared publication
  • Hiroyuki Abe

    Kudan Clinic, 1-9-5 Kudankita, Chiyoda-ku, Tokyo 102-0073, Japan

    1 shared publication
  • Maho Kobayashi

    The Life Science Institute Ltd., 1-10-9 Kudankita, Chiyoda-ku, Tokyo 102-0073, Japan

    1 shared publication
  • Rie Kohosozawa

    The Life Science Institute Ltd., 1-10-9 Kudankita, Chiyoda-ku, Tokyo 102-0073, Japan

    1 shared publication
  • Rika Nishiko

    The Life Science Institute Ltd., 1-10-9 Kudankita, Chiyoda-ku, Tokyo 102-0073, Japan

    1 shared publication

Latest Publications

  • Detection of aberrant methylation of tumor suppressor genes in plasma from cancer patients

    by Hiroaki Kawasaki, Emi Igawa, Rie Kohosozawa, Maho Kobayashi, Rika Nishiko, Hiroyuki Abe

    Purpose: For personalized medicine, a novel biomarker is necessary for screening and monitoring of cancer. DNA methylation of the promoter region of tumor suppressor gene(s) has been detected in tumor tissue and plasma/serum from patients with various types of cancer. To investigate the methylation status of gene promoters in plasma from cancer patients, we examined the frequency of methylation in the promoter regions of the APC, DCC, p16INK4a, p14ARF, and RASSF1A genes in plasma. Methods: Samples of plasma were obtained from 244 patients with colon cancer, lung cancer, pancreatic cancer, gastric cancer, hepatocellular carcinoma, and breast cancer. Cell-free DNA was extracted from each plasma sample and the methylation status of the promoters of the APC, DCC, p16INK4a, p14ARF, and RASSF1A genes were examined by methylation-specific PCR. Results: Methylation of the promoter of the APC and RASSF1A genes was detected in plasma from patients with each type of cancer. Notably, methylation of the APC and RASSF1A promoters was detected in plasma from patients with HCC at a high frequency. However, the frequency of methylation of the promoters of the DCC and p14ARF genes from patients with HCC was lower than that of patients with colon cancer. Conclusion: Our results indicate that the frequency of methylation of cancer-related genes is dependent on the type of cancer and patient. Therefore, DNA methylation of cancer-related genes has a high potential as a biomarker for personalized medicine.